Possible mechanical causes of scaffold thrombosis: Insights from case reports with intracoronary imaging

EuroIntervention

Volumn 12, Issue 14, 2017, Pages 1747-1756

  Sotomi, Yohei ^a   Suwannasom, Pannipa ^a,b,c   Serruys, Patrick W ^d   Onuma, Yoshinobu ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bioresorbable scaffold; Intravascular ultrasound; Mechanical cause; Optical coherence tomography; Scaffold thrombosis

Indexed keywords

ATHEROSCLEROSIS; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CASE STUDY; DRUG ELUTING SINUS STENT; HUMAN; INTRAVASCULAR ULTRASOUND; MEDICAL DEVICE COMPLICATION; NEOATHEROSCLEROSIS; NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCAFFOLD THROMBOSIS; STENT THROMBOSIS; THROMBOSIS; ADVERSE DEVICE EFFECT; CORONARY BLOOD VESSEL; DRUG ELUTING STENT; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT;

CARDIOVASCULAR AGENTS; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 85016011234     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJ-D-16-00471     Document Type: Review

References (68)

1. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-40.
2. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
3. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569-77.
4. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Munzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144-53.
5. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66: 2298-309.
6. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, Stone GW; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332-42.
7. Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, Baan J Jr, Vis MM, Arkenbout EK, Tijssen JG, de Winter RJ, Wykrzykowska JJ. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention. 2015;10:1160-8.
8. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdes M, Widimsky P, Serruys PW, Sabaté M. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015;8:189-97.
9. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277-89.
10. Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation. 2009;119:657-9.
11. Fernandez-Rodriguez D, Brugaletta S, Otsuki S, Sabaté M. Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? EuroIntervention. 2014;10:600; discussion 600.
12. Jaguszewski M, Wyss C, Alibegovic J, Luscher TF, Templin C. Acute thrombosis of bioabsorbable scaffold in a patient with acute coronary syndrome. Eur Heart J. 2013;34:2046.
13. Karanasos A, van Geuns RJ, Zijlstra F, Regar E. Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy. Eur Heart J. 2014;35:1781.
14. Karanasos A, Van Mieghem N, van Ditzhuijzen N, Felix C, Daemen J, Autar A, Onuma Y, Kurata M, Diletti R, Valgimigli M, Kauer F, van Beusekom H, de Jaegere P, Zijlstra F, van Geuns RJ, Regar E. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv. 2015;8(5).
15. Miyazaki T, Panoulas VF, Sato K, Naganuma T, Latib A, Colombo A. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Int J Cardiol. 2014;174:e72-4.
16. Abu Sharar H, Katus HA, Bekeredjian R. Pitfalls of bioresorbable vascular scaffold thrombosis-be sure to cover it all. Int J Cardiol. 2014;177:1067-8.
17. Ishibashi Y, Onuma Y, Muramatsu T, Nakatani S, Iqbal J, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Abizaid A, Serruys PW; ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention. 2014;10:449-57.
18. Raber L, Brugaletta S, Yamaji K, O'Sullivan CJ, Otsuki S, Koppara T, Taniwaki M, Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabate M, Windecker S. Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. J Am Coll Cardiol. 2015;66:1901-14.
19. Schiattarella GG, Magliulo F, D'Alise G, Mannacio V, Ilardi F, Trimarco B, Esposito G, Cirillo P. The pitfalls of managing thrombosis of an Absorb™-treated bifurcation. Int J Cardiol. 2014;174:e93-5.
20. Hamm C. 30-days follow up of the German-Austrian-ABSORB Register: GABI-R (abstract). Presented at: EuroPCR. Paris, France, 2015.
21. Azzalini L, Al-Hawwas M, L'Allier PL. Very late bioresorbable vascular scaffold thrombosis: a new clinical entity. EuroIntervention. 2015;11:e1-2.
22. Azzalini L, L'Allier PL. Bioresorbable vascular scaffold thrombosis in an all-comer patient population: single-center experience. J Invasive Cardiol. 2015;27:85-92.
23. Chevalier B, Serruys PW. The 2-year clinical outcomes of the ABSORB II trial: first randomized comparison between the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE everolimus-eluting stent. Presented at Transcatheter Cardiovascular Therapeutics (TCT). San Francisco, CA, USA, 2015.
24. Cortese B, Piraino D, Ielasi A, Steffenino G, Orrego PS. Very late bioresorbable vascular scaffold thrombosis due to late device recoil. Int J Cardiol. 2015;189:132-3.
25. Cuculi F, Puricel S, Jamshidi P, Valentin J, Kallinikou Z, Toggweiler S, Weissner M, Munzel T, Cook S, Gori T. Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis. Circ Cardiovasc Interv. 2015;8:e002518.
26. Ho HH, Er Ching M, Ong PJ, Ooi YW. Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases. Heart Vessels. 2015;30:545-8.
27. Ielasi A, Cortese B, Steffenino G. Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis. JACC Cardiovasc Interv. 2015;8:e171-2.
28. Meincke F, Spangenberg T, Heeger CH, Bergmann MW, Kuck KH, Ghanem A. Very Late Scaffold Thrombosis Due to Insufficient Strut Apposition. JACC Cardiovasc Interv. 2015;8:1768-9.
29. Timmers L, Stella PR, Agostoni P. Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy. Eur Heart J. 2015;36:393.
30. Yahagi K, Virmani R, Kesavamoorthy B. Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovasc Interv Ther. 2017;32:53-5.
31. Sabaté M, Windecker S, Iniguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Räber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229-40.
32. Foin N, Gutierrez-Chico JL, Nakatani S, Torii R, Bourantas CV, Sen S, Nijjer S, Petraco R, Kousera C, Ghione M, Onuma Y, Garcia-Garcia HM, Francis DP, Wong P, Di Mario C, Davies JE, Serruys PW. Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition. Circ Cardiovasc Interv. 2014;7:180-9.
33. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, Binder H, Eggebrecht H, Munzel T, Cook S, Gori T. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016;67:921-31.
34. Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Chevalier B, Abizaid A, Ormiston JA, Rapoza RJ, Veldhof S, Onuma Y, Serruys PW. Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8:1715-26.
35. Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7:1400-11.
36. Tellez A, Afari ME, Buszman PP, Seifert P, Cheng Y, Milewski K, McGregor JC, Garza JA, Roberts MB, Yi GH, Kaluza GL, Granada JF. Peri-strut low-intensity areas in optical coherence tomography correlate with peri-strut inflammation and neointimal proliferation: an in-vivo correlation study in the familial hypercholesterolemic coronary swine model of in-stent restenosis. Coron Artery Dis. 2014;25:595-601.
37. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobaltchromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330-42.
38. Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, Thuesen L, McClean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Chevalier B, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv. 2011;4:1271-80.
39. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354-63.
40. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59:1337-49.
41. Koppara T, Cheng Q, Yahagi K, Mori H, Sanchez OD, Feygin J, Wittchow E, Kolodgie FD, Virmani R, Joner M. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv. 2015;8:e002427.
42. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24.
43. Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, Achenbach S, Pan Alvarez M, Nef H, Lesiak M, Di Mario C, Colombo A, Naber CK, Caramanno G, Capranzano P, Brugaletta S, Geraci S, Araszkiewicz A, Mattesini A, Pyxaras SA, Rzeszutko L, Depukat R, Diletti R, Boone E, Capodanno D, Dudek D. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015;11:45-52.
44. Mangiameli A, Ohno Y, Attizzani GF, Capodanno D, Tamburino C. Neoatherosclerosis as the cause of late failure of a bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2015;8: 633-4.
45. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801.
46. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373:1905-15.
47. Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Chevalier B, Smits P, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Wasungu L, Ediebah D, Veldhof S, Onuma Y. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J Am Coll Cardiol. 2016;67:766-76.
48. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999-1009.
49. Dudek D, Rzeszutko L, Zasada W, Depukat R, Siudak Z, Ochala A, Wojakowski W, Przewlocki T, Zmudka K, Kochman J, Lekston A, Gasior M. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn. 2014;124:669-77.
50. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T. Early outcome after implantation of Absorb bioresorbable drugeluting scaffolds in patients with acute coronary syndromes. EuroIntervention. 2014;9:1036-41.
51. Ko?ka V, Malý M, Touŝek P, Bud?ŝínský T, Lisa L, Prodanov P, Jarkovský J, Widimský P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J. 2014;35: 787-94.
52. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35:777-86.
53. Wiebe J, Mollmann H, Most A, Dorr O, Weipert K, Rixe J, Liebetrau C, Elsasser A, Achenbach S, Hamm C, Nef H. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103:141-8.
54. Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. Am J Cardiol. 2015;116:705-10.
55. Ielasi A, Cortese B, Varricchio A, Tespili M, Sesana M, Pisano F, Loi B, Granata F, Moscarella E, Silva Orrego P, La Vecchia L, Steffenino G; RAI registry investigators. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre Registro ABSORB Italiano (RAI registry). EuroIntervention. 2015;11:157-62.
56. Abizaid A, Ribamar Costa J Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong WF, Sudhir K, Serruys PW; ABSORB EXTEND investigators. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015;10:1396-401.
57. Felix C, Fam JM, Onuma Y, Ishibashi Y, Everaert B, Diletti R, Regar E, Van Mieghem NM, Daemen J, De Jaegere P, Zijlstra F, Van Geuns RJ. TCT-527 Long-term Clinical Outcomes of Patients Treated With The Everolimus-eluting Bioresorbable Vascular Scaffold. The BVS Expand Study. J Am Coll Cardiol. 2015;66(15-S).
58. Robaei D, Back L, Ooi SY, Pitney M, Jepson N. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. J Invasive Cardiol. 2016;28:316-22.
59. Jaguszewski M, Ghadri JR, Zipponi M, Bataiosu DR, Diekmann J, Geyer V, Neumann CA, Huber MA, Hagl C, Erne P, Lüscher TF, Templin C. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol. 2015;104:124-35.
60. Costopoulos C, Latib A, Naganuma T, Miyazaki T, Sato K, Figini F, Sticchi A, Carlino M, Chieffo A, Montorfano M, Colombo A. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv. 2015;85:E10-5.
61. Nef H, Wiebe J, Achenbach S, Munzel T, Naber C, Richardt G, Mehilli J, Wohrle J, Neumann T, Biermann J, Zahn R, Kastner J, Schmermund A, Pfannebecker T, Schneider S, Limbourg T, Hamm CW. Evaluation of the short-and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R). Cardiovasc Revasc Med. 2016;17:34-7.
62. Hernandez F, Pérez de Prado A, Salinas P, Piñon P, Bassaganyas J, Bosco AT, Avanzas P, Sanchis J, Lozano I, Lopez-Minguez JR, Gaviria K, Masotti M, Andraka L, Alonso Briales JH, Moreno R, Berenguer A, Romero PM. TCT-544 Bioresorbable Coronary Devices in Clinical Practice: Immediate and 30-day Results of the Prospective REPARA Registry. J Am Coll Cardiol. 2015;66(15-S).
63. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, Garcia-Garcia HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, Stone GW, Abizaid A, Serruys PW; ABSORB Cohort B Investigators; ABSORB EXTEND Investigators; SPIRIT FIRST Investigators; SPIRIT II Investigators; SPIRIT III Investigators; SPIRIT IV Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv. 2014;7:482-93.
64. Wöhrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, Brachmann J, Ingwersen M, Drabik A, Markovic S, Mathey DG. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention. 2015;11:149-56.
65. Vaquerizo B, Barros A, Pujadas S, Bajo E, Estrada D, Miranda-Guardiola F, Rigla J, Jimenez M, Cinca J, Serra A. Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study. EuroIntervention. 2015;11:555-63.
66. Moscarella E, Varricchio A, Stabile E, Latib A, Ielasi A, Tespili M, Cortese B, Calabro P, Granata F, Panoulas VF, Franzone A, Trimarco B, Bonzani G, Esposito G, Colombo A. Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian experience. Int J Cardiol. 2015;199:366-72.
67. Ielasi A, Latib A, Naganuma T, Cortese B, Sato K, Miyazaki T, Panoulas VF, Tespili M, Colombo A. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. Int J Cardiol. 2014;173:513-4.
68. Suárez de Lezo J, Martín P, Pan M, Ojeda S, Nóvoa J, Segura J, Mazuelos F, Romero M, Medina A, Suárez de Lezo J. Bioresorbable Vascular Scaffold for the Treatment of Coronary Bifurcation Lesions: Immediate Results and 1-year Follow-up. Rev Esp Cardiol (Engl Ed). 2016;69:554-62.